Coming Soon: Lucina Biosciences

---

Lucina Biosciences is using advanced science to develop therapeutics to combat aging and enhance longevity

Aging is the leading risk factor in multiple disorders impacting health span, lifespan, and quality of life. Aging related decline in tissue levels of a class of lipids known as VLC-PUFA driven by epigenetic changes in the ELOVL2 gene accelerate aging,    Lucina has developed proprietary yeast designed to restore tissue concentrations of the critical VLC-PUFA following oral administration to slow cellular aging.

An estimated 200 million people worldwide suffer from aging related vision loss.  Recent scientific studies have identified declining retinal concentrations of VLC-PUFA's  as a causal factor and that restoration of retinal VLC-PUFA significantly improves the visual signal and rejuvenates retinal cellular architecture. 

VLC-PUFA deficits are  associated with multile aging related disorders including:

Osteoporosis (1)                                                                                       Decline in Learning and Memory (1,4)

Loss of Glucose Tolerance / Insulin Sensitivity (1)                Male Infertility (3)                    

Increased Cardiovascular Events (1,5)                                        Immune Dysfunction (2)

Hepatic Fibrosis and Steatosis (1)

References:

1.Li et al., Signal Transduction and Targeted Therapy, 7 (162), 20222.

2.Vincenzi et al., bioRxiv Preprint, September 2024

3.Gavrizi et al., Fertility & Sterility, 119 (5), 2023

4.Taoro-Gonzalez et al., International Journal of Molecular Sciences, 23 (130), 2022

5.Yang et al., iScience, 26: 108411, 2023